Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call. This call is being recorded on Tuesday, May 6, 2025. I would now like to turn the conference over to Kellen Sanger, SOPHiA GENETICS Head of Strategy and Investor Relations. Please go ahead.

Thank you, and good morning, everyone. Welcome to the SOPHiA GENETICS First Quarter 2025 Earnings Conference Call. Joining me today to discuss our results are Dr. Jurgi, our Co-Founder and Chief Executive Officer; Ross Muken, our company President; and George Cardoza, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release issued by SOPHiA GENETICS today and in the documents and reports filed by SOPHiA GENETICS from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's press release, which is available on our website. With that, I'll now turn the call over to Jurgi.

Thanks, Kellen, and good morning, everyone. I will start today's call with a brief recap of Q1 performance, which came in slightly ahead of our expectations as growth reaccelerated and cost management continues to improve. I will then turn the call over to Ross, who will give a more detailed update on the business. George will close with a review of our Q1 financial performance before we take your questions. Last quarter, we highlighted that 2024 was a foundational year for SOPHiA. We laid the groundwork for accelerated growth in 2025 by signing an impressive cohort of new customers, continuing to penetrate the U.S. market, and launching new and exciting applications such as MSK ACES and MSK Impact. In Q1, these efforts began to materialize. Revenue grew 15% on a constant currency basis and 13% on a reported basis, representing a solid movement toward near historical growth levels. Going forward, we expect to deliver accelerating revenue growth along the 3 drivers we outlined at the beginning of the year. First, we will capitalize on new customer signings by expediting implementation times and expanding across those new accounts over time. In 2024, we signed an impressive 92 new core genomic customers, and in Q1 2025, we added 28 new customers to that total. Our focus continues to be on implementing these new customers as quickly as possible so that they begin generating revenue faster. We implemented 33 new customers in the first quarter, up from an average of 23 per quarter last year. I look forward to these customers ramping up usage over the next few months and adopting additional applications over time. The second growth driver we will continue to focus on is the U.S. market. In Q1, revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year. The impressive growth was delivered off an ever-expanding revenue base as the country is becoming one of our largest markets globally. On the new business side, we also announced major expansions at two of the leading hospitals in the U.S., with Henry Ford Hospital adopting additional solid tumor and HemOnc applications, and the Mayo Clinic adopting additional applications in HemOnc. Congrats to the team for this impressive Q1 achievement. Our third focus area for 2025 is MSK-ACC and Impact, our new liquid biopsy and solid tumor applications. While clinical adoption continues at impressive rates, I'm happy to highlight that these applications are also attracting material interest from biopharma partners. Last week, we expanded our 2024 partnership with AstraZeneca to accelerate the deployment of MSK-ACCES globally. The expansion extends the scope of the partnership to 30 total sponsored institutions worldwide. The agreement also highlights the growing demand for somatic testing as applications like MSK-ACCES are becoming invaluable to biopharma for purposes of drug deployment and market access. In addition, the data generated from this test and the diverse patient populations they reach offer immense value to biopharma for drug development and commercialization. In Q1, it was great to see the clinical and biopharma flywheel spinning again as our growing network began attracting new interest from biopharma. I am excited to keep you updated over the course of the year as our flywheel gains speed and revenue growth continues to accelerate. Beyond starting the year strong on the revenue side, I am also proud of the team for continuing to excel at cost management. In Q1, we delivered an impressive 24% year-over-year improvement to adjusted EBITDA loss, bringing the figure down to $9.8 million in the quarter. As we continue on our path to profitability, we believe this achievement serves as a proof point for the scalable nature of our business and our ability to drop incremental revenue growth down to the bottom line. In many ways, scalability was a theme this quarter. In Q1, we delivered a record 75.7% adjusted gross margin, up 520 basis points year-over-year. This achievement was made possible by innovations from our tech and data science teams who continue to discover new ways to optimize the data compute and processing power of our platform. These improvements are especially impressive because they were delivered despite massive increases in the amount of data processed by SOPHiA DDM over the year. Total processed by the platform has increased at a CAGR of over 50% from 2021 to 2024. While analysis volumes continue to grow, so does the complexity of data. Gene panels are becoming larger, additional modalities are becoming more useful, and more sophisticated tests are being deployed each day. Our scalable cloud-based platform is designed to support the medical innovations of today and tomorrow, deploying new innovations with accuracy and efficiency. Whether it is liquid biopsy testing, HRD, whole genome sequencing, or MRD, the scalable nature of our platform and its AI factories enable us to bring bioinformatic breakthroughs from the research lab to the clinical market with relative ease. In this way, we are perfectly positioned to push waves of innovation in healthcare for years to come. However, this ability and the AI that enables it has not been achieved by chance. In Q1, we reached an impressive milestone for our platform. As of March, SOPHiA DDM has now analyzed over 2 million genomic patient profiles since inception. This means that the AI powering SOPHiA DDM is uniquely trained on one of the most diverse and globally representative data sets available, learning from a constant flow of real-world data from over 800 institutions in 70 countries worldwide. Technology companies across the space are increasingly recognizing the breadth and diversity of our data set and how our network and AI capabilities are nearly impossible to replicate. In March, I spoke at the NVIDIA GTC Conference in San Jose, California, about how SOPHiA is pioneering the practical use of AI in healthcare. The conference reinforced what we are already seeing in the market. AI is no longer a future promise, but a present force reshaping how we diagnose, treat, and understand disease. It also reinforced that SOPHiA is a leader in this space. Our platform, AI factories, and global network place us soundly at the center of the future of healthcare. With that, I will now turn the call over to Ross, who will provide a more detailed update on what we are seeing in the market and our business performance to start the year.

Thanks, Jurgi. The go-to-market team share your excitement and confirm there is broad and growing demand for the SOPHiA offering. Along those lines, I'll start today by giving a brief update on our first quarter performance, including a strong start to the year across both new and existing business. I'll then cover some of the broader market dynamics before closing with a look at what we're seeing in the pipeline. First, the core business returned to healthy levels as revenue grew 15% on a constant currency basis in the first quarter despite biopharma continuing to present some modest headwinds. We are proud to have reaccelerated the growth engine of the core business, and the biopharma pipeline is again developing well. On the clinical side, from a regional perspective, North America and Asia Pacific continued to outperform in Q1 with 32% and 40% year-over-year volume growth, respectively. Latin America declined slightly due to the acquisition of one of our top customers in the region by another lab, which we covered in detail in 2024. EMEA volume growth remains solid, with the United Kingdom as a notable driver. Last year, we announced a series of new customer signings across the U.K., including 5 of the 7 NHS genomic laboratory hubs adopting SOPHiA DDM. Due to these signings and others, U.K. analysis volume grew over 60% year-over-year, and U.K. revenue was up approximately 80%. From an application standpoint, we continue to establish ourselves as a global leader in HemOnc testing. HemOnc volumes grew 34% year-over-year in the first quarter off an increasingly large base. With over 180 HemOnc customers globally, we believe we are one of the largest providers of blood-based cancer testing in the world, an area of critical importance to both our clinical and biopharma constituents. We are confident HemOnc will continue to be a growth driver for our future growth. Beyond HemOnc, we also started the year strong in solid tumors as volumes grew well above the company average. New applications such as MSK-IMPACT and an upgraded CGP offering are solidifying our offering as the gold standard for comprehensive tissue testing. Last, the first wave of liquid biopsy testing began to come online in Q1, albeit in very modest initial volumes. We will look to the back half of the year for liquid biopsy applications such as MSK-ACCESS to meaningfully drive overall growth as customers complete implementation and ramp up usage over 2025. Moving to the new business side. I am happy to share that in Q1, we continued to book new business at record speeds. We landed 28 new core genomic customers in the quarter, up from 20 new customers signed in the first quarter of 2024. In addition, we also had many notable expansions as the influx of new customers over the past year look to adopt initial applications. In North America, Jurgi announced our recently expanded partnerships at Henry Ford and the Mayo Clinic. In addition, we also expanded our scope with Sunnybrook Health Science Center in Toronto, Canada. Sunnybrook was already using the SOPHiA DDM for solid tumor HRD testing, and now they are adopting additional applications for HemOnc. On the landside, we signed LifeLabs in Q1, a major central reference lab in Canada. LifeLabs, Canada's largest community lab, which performs over 100 million lab tests annually, is adding SOPHiA DDM for solid tumor testing. Lastly, we also announced the signing of Mount Sinai during the quarter, adding to the growing list of leading institutions in the U.S. using SOPHiA. In EMEA, I am excited to highlight the signing of Jessa in Belgium. Jessa is one of the largest hospitals in Belgium located in Hasselt, and they will adopt SOPHiA DDM for solid tumor, liquid biopsy, and HemOnc testing. This signing represents one of the largest wins of the last year. Congrats to the EMEA team on this significant new addition. Beyond Western Europe, we continue to see growing adoption across the Middle East. During the quarter, we announced our partnership with M42, an Abu Dhabi-based world health leader that is implementing MSK-ACCESS at select hospitals throughout the UAE. Through this collaboration, we look forward to bringing best-in-class liquid biopsy testing to patients across the Middle East. Moving to Asia Pacific. We continue to see strong and growing interest. In the first quarter, we announced a new partnership with Genesis Healthcare to bring SOPHiA solutions to the Japanese market. We look forward to keeping you updated on our progress as this would be a critical new market for us in the coming years. Beyond Japan, I'd like to highlight the signing of Premier Integrated Lab, a leading diagnostic lab in Malaysia that is adopting numerous applications in hereditary cancer, HemOnc, and inherited disorders in addition to MSK-ACCESS. Lastly, in Latin America, we continue to make strides across the region. In Q1, we signed BiomaGenetics, a Brazilian-based precision medicine provider that is adopting SOPHiA DDM for HRD solid tumors and Hospital de Amore in Barretos, Brazil that is adopting MSK-ACCESS. Welcome Bioma and Hospital de Amore to the SOPHiA community. In conclusion, new business remains strong across all geographies. We continue to sign new customers at impressive rates. And in addition, the average contract value of signings continues to increase with ACVs on new business up materially year-on-year. This is due in part to increasing success in enterprise-level sales pitching and in part due to industry-wide shift toward more sophisticated bioinformatic applications. We continue to see demand in the market for large gene panels, bigger sequencers, and more depth. Our liquid biopsy application, MSK-ACCESS, is a perfect proof point. MSK-ACCESS covers over 146 genes and relies on an advanced proprietary molecular barcoding algorithm called Human to detect variants and generate insights. On the solid tumor side, we are also seeing demand for larger CGPs as well as the ability to track disease over time. Last year, we announced the launch of MRD capabilities on SOPHiA DDM for acute myeloid leukemia, and we plan to expand the MRD features to additional applications such as solid tumors over time to serve our customers across the globe, including in Europe. So in short, the clinical new business pipeline continues to reach record levels as bioinformatic insights become more and more valuable. But growing demand doesn't stop with our clinical users. On the biopharma side, our pipeline is also reaching record highs. The revamped diagnostic offering is attracting more interest than ever. Opportunities range from sponsored testing partnerships like the expanded collaboration we recently signed with AstraZeneca to other projects focused on helping biopharma strengthen their clinical development programs and improve market access. I joined the team at World CB and CDx Conference in London last month and was thrilled to see the activity level and number of meetings we have with the top 20 biopharma, including names such as J&J and Cartos. On the biopharma data side, we are beginning to see promising momentum as well. Our multimodal data offering, including the use of our AI factories to produce data structuring and predictive analytics, is gaining interest from top biopharma, particularly in the areas of lung and kidney cancer. We look forward to keeping you updated this year on the overall progress of the biopharma business. To conclude, I'm proud of the team for delivering an excellent quarter, and I'm also encouraged by the growth of our pipeline and of our end markets. With that, I will now turn the call over to George, who will provide a more detailed look at our Q1 financial results.

Thank you, Ross, and good morning, everyone. As Jurgi and Ross highlighted, Q1 results came in slightly ahead of expectations as new business from 2024 begins to come online. Total revenue for the first quarter of 2025 was $17.8 million compared to $15.8 million for the first quarter of 2024, representing year-over-year growth of 13%. On a constant currency basis, year-over-year revenue growth was 15% as foreign exchange headwinds negatively impacted reported revenue by approximately $400,000. Platform analysis volume was approximately 93,000 for the first quarter of 2025 compared to approximately 84,000 for the first quarter of 2024, representing year-over-year growth of 11%. Core genomic customers were 490 as of March 31, up from 463 in the prior year period and up sequentially by 18 customers relative to Q4 2024. While we added 33 new customers in the quarter, we churned out a few smaller accounts who had not generated revenue over the past 12 months. Nonetheless, Q1 revenue churn remained low at approximately 4%, which is in line with our historical averages. Net dollar retention for the quarter was 103%, driven primarily by the decline in growth in Latin America. Gross profit for the quarter was $12.2 million compared to gross profit of $10.4 million in the prior year period, representing year-over-year growth of 17%. Gross margin was 68.7% for the first quarter of 2025 compared with 65.9% for the first quarter of 2024, up 273 basis points year-over-year. Adjusted gross profit was $13.4 million, an increase of 21% compared to adjusted gross profit of $11.1 million in the prior year period. Adjusted gross margin reached a record high of 75.7% for the first quarter of 2025, up 520 basis points from 70.6% in the first quarter of 2024. As Jurgi mentioned, targeted platform improvements throughout the year continue to drive cloud compute costs and storage costs lower, an achievement we remain proud of and plan to continue throughout the year. Total operating expenses for Q1 were $28.2 million compared to $29.2 million in the first quarter of 2024, representing an improvement of 3% year-over-year. R&D expenses decreased during the quarter as we increasingly focused on high ROI projects. Additionally, I remain pleased with our progress on the G&A side, where we also continue to benefit from targeted process improvements, system investments, and the optimization of our public company costs. Sales and marketing expenses were up a touch, primarily due to select investments oriented at accelerating penetration of several key markets as well as marketing initiatives to support our robust new product momentum. Operating loss for the quarter was $16 million compared to $18.8 million in the prior year period. Adjusted operating loss was $10.8 million compared to $14.1 million for the first quarter of 2024, representing an improvement of 23% year-over-year. EBITDA loss for the first quarter was $13.7 million compared to $16.7 million in the prior year period. Adjusted EBITDA loss for Q1 was $9.8 million compared to $12.9 million in Q1 of 2024, an improvement of 24% year-over-year. We remain proud of our ability to drop revenue growth down to the bottom line while also reducing costs across the P&L. We continue to be highly disciplined with respect to headcount, where we have focused on optimizing growth and scalability. We also continue to scrutinize all direct and indirect expenditures, ensuring a balanced focus on hitting our growth targets and achieving the operational efficiencies desired. We hope this performance serves as a proof point for our ability to reach our commitment to be approaching adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027. Lastly, total cash burn, which we define as the change in cash and cash equivalents for the first quarter of 2025 was $11.7 million compared to $19.5 million in the prior year quarter. Excluding the impact of exchange rate differences, cash burn improved approximately $3 million in Q1 as compared to the prior year period. We finished the quarter with cash and cash equivalents of approximately $68.5 million as of March 31, 2025. As a reminder, we currently have access to an additional $35 million of capital through the financing line with Perceptive Advisors. We remain confident in our current capital position with respect to the achievement of our goals. I'll now turn to the 2025 outlook. Given the promising reacceleration of clinical growth in Q1, SOPHiA GENETICS is reaffirming our full-year revenue guidance for 2025 of $72 million to $76 million, representing 10% to 17% growth on a reported basis. Despite a slightly stronger-than-expected quarter, we still maintain that 2025 will be mostly back half weighted as new business signed in 2024 comes online in the second half of the year and its MSK-ACCESS business begins to ramp up to routine usage. As a reminder, we expect Q4 to continue being the strongest quarter seasonably during the year. We also expect that exchange rates will be volatile due to macro uncertainties, which may have an impact on reported results. Beyond revenue, we are also reaffirming our full-year adjusted EBITDA loss guidance of $35 million to $39 million. As demonstrated this quarter, we continue to make targeted investments in our platform to optimize cloud compute and storage costs and expect to expand gross margin beyond 2024 levels. As a global company, we are watching the developments on the tariff front as most are. First, I'll remind you that SOPHiA DDM is an AI Software-as-a-Service platform. We offer our customers 3 methods of accessing the platform with dry lab, bundle, and integrated access modes. The bundle access mode includes SOPHiA DDM plus consumables. We have one assembly line located in Roll, Switzerland, and we ship consumables globally from there. This includes some shipments to the United States. Of our $9 million in U.S. revenue in 2024, the total value of consumable shipments to the U.S. was only approximately $800,000. Even with growth in 2025, a 10% tariff would be manageable. The tariff also apparently is to be reduced by raw materials sourced in the U.S. and in fact, many of our raw materials are sourced there. While the situation is fluid at this present time, we don't believe the impact to SOPHiA GENETICS to be very material. We also expect to continue to largely hold the line on operating expenses as we currently have the correct team size to support our medium-term growth objectives. This excludes some high ROI investments we will continue to make related to marketing activities as well as certain investments in the commercial team. Lastly, we will continue to revisit our discretionary expenditures and execute on identified savings in systems, professional services, and certain public company costs throughout 2025. The combined nature of these items and the natural operating leverage in the business from strong revenue growth will further our path to profitability in the next two years. With that, I would like to turn the call back over to Jurgi for the closing remarks before we take your questions.

Thank you, George. I am proud of what the team achieved this quarter. We took a major first step during Q1, accelerating revenue growth to 15% constant currency, expanding adjusted gross margins again, now up to 75.7%, and improving adjusted EBITDA by 24% year-over-year. The quarter sets the tone for a strong 2025. Looking ahead, bookings momentum remains strong and end markets continue to grow. Our offering sits at the center of concentric trends in healthcare. We have built an expansive global network of customers and dynamic AI capabilities, which generate critical insights for a growing number of cancer and rare disease patients globally. Better therapies are being developed each day and data-driven medicine has become the new basis for diagnosis, therapy selection, and follow-on testing in addition to drug development and deployment. Given our business sits at the center of these innovations, we remain confident in our long-term growth. In closing, I want to say thank you to our SOPHiA colleagues, partners, customers, and investors for joining us in our journey to transform patient care with data-driven medicine. Please note, we are presenting at the RBC Conference on May 20 and 21 in New York City. We all look forward to continuing to update you on SOPHiA's future success of democratizing data-driven medicine around the world. Operator, you may now open the line for questions.

Your first question comes from the line of Bill Bonello with Craig-Hallum. Please go ahead.

Good morning guys, nice quarter. Just a couple of follow-up questions. First, you talked about accelerating the time frame for implementation, and we are seeing that in the good implementation numbers. Can you talk just a little bit about the kinds of actions that you've been able to take that actually allow you to implement more quickly than maybe you have been able to do so in the past?

Yes. Thank you, Bill. So indeed, right, to start with the numbers first. As we highlighted this quarter, we implemented 33 new customers versus an average of 23 customers per quarter for 2024. And obviously, this is as well the result of bookings that have been improving over time. So specifically on the implementations, Ross has been scaling up team capabilities, and we'll give you a bit more color.

Thank you, Bill. This has clearly been a significant area of focus for us. Throughout last year, we discussed our efforts to accelerate bookings momentum, which we anticipated would put some strain on our implementation teams due to the increasing number and complexity of implementations. Our deal sizes are also rising, particularly for liquid biopsy implementations, which are more intricate. To address this, we have developed new tools and automation processes to improve our execution and expedite various elements of implementation. Additionally, we have integrated industrialization into our processes to better understand the time required for each stage and to troubleshoot any challenges that may arise in the lab. We have also slightly increased our headcount, particularly among wet lab and field application scientists who collaborate closely with clinicians. This combined approach involving tools, process enhancements, and strategic hires has allowed us to significantly accelerate our implementation processes.

That's very helpful. My second question is about the increase in average contract value. We would expect this due to the more complex analyses being added. You also mentioned enterprise sales, and I want to ensure I understand that correctly. Are you referring to customers who, instead of starting with just one or two applications, are now utilizing DDM for all their NGS testing? If so, could you clarify why you believe there is an increase in this area? Is there a shift in the overall environment that is making it more challenging for clients to handle bioinformatics independently, or is your company actively pushing to sell at the enterprise level? Could you elaborate on that?

Yes. Sure, Bill. So I will start and then let Ross further develop. So indeed, as you know, our platform has multiple capabilities, right, for multiple disease areas, such as solid tumors, hereditary cancer, liquid biopsy, and rare neuro disorders. And for each of these areas, our platform can be used for multiple types of applications and multiple types of test kits. So today, it's 58% of our customers who are using two or more applications. So definitively, there is room to expand the utilization of applications per customer. And you're absolutely right in your understanding of the enterprise concept. These are deals where when we get in, we're basically signing for a majority of all the applications they are covering, right, unlike when we are landing a customer only for liquid biopsy. So Ross, maybe you want to give a bit more color on what you're seeing, especially when it comes to the bioinformatics in the field and clarify whether the ACV being doubled year-on-year on a contract basis will primarily come from that or from more complex solutions or a mix.

Thanks, Jurgi. And it's a really good question, Bill. This is probably one of the most important dynamics of what's happening in the market. And it really speaks to a point Jurgi touched on and you made around the complexity of what is being analyzed now in many laboratories. And so if you think about the evolution of the market as we've gone from single gene to multi-gene or pan tumor and then more complex capabilities like CGP, exome, whole genome, MRD, etcetera. Now many laboratories have multiple types of sequencers, multiple types of assays or chemistry they are running, maybe different automates and a mix of homegrown and then maybe SOPHiA or other solutions. And as the complexity continues to go up, it becomes completely unmanageable from an efficiency and cost perspective, particularly as data is growing, let's say, north of 50% in terms of output in many of these laboratories. And so the desire to then simplify across the workflows and harmonize a common platform will gain you massive leverage in your laboratory where many still are, I would say, human capital constrained. And so that's really playing to our strength, particularly with our universal library prep and then with the uniformity of our workflows around different applications. And so this is attracting more and more laboratories to basically sunset either existing homebrew solutions and/or consolidate competitor solutions to us. And we think this will only accelerate as we have more examples of this. Obviously, in Q1, we called out Jessa, a very large lab in Belgium. This is a great example, but we will have many more over the coming quarters. If I look at my pipeline, the number of multi-application deals is up materially year-on-year, and this is quite important. I would say, on top of that, if you think as well about what's happening in the sequencer market and just the higher output per sequencer, which again is moving people to more and more sophisticated applications internally, that as well begs a lot of the question of driving that shift. And so I think the more you see multi-manufacturer sequencers present in accounts and then higher throughput sequencers present in accounts, this will continue to push things in our favor. And lastly, I would just say this has also been a concerted effort, right? We really spent a lot of time this year from a targeting and focus perspective from a go-to-market team at Salesforce and saying, all right, we won some really mega names around the world. If you look at our presence in the top 20, top 50, and top 100 cancer institutions in central laboratories, we really have now the right to compete in these much bigger accounts. So we put a real emphasis on driving higher ACVs. And I think that will continue to tick up throughout the year and particularly with success we're having in the U.S. market and in markets like the U.K. and Germany, etcetera, and eventually Japan, I think that will also positively benefit that metric and allow us to not only grow at the rates we expect, which are improved, but also become more efficient as obviously, you can service for us a $1 million account similarly as you can service a $200,000 account, and so you get operating leverage in that as well.

Excellent. Thank you so much.

And your next question comes from the line of Conor McNamara with RBC Capital Markets. Please go ahead.

Hey guys, thanks for taking the questions and congrats on a solid quarter. Just on the gross margins, they came in a lot stronger than anticipated. Was there anything one-time in there? Or are these gross margins sustainable above 75% going forward?

Hey good morning Conor. So first, maybe you remember that we've been continuously speaking on improving as well our algorithms, right? So that while the data compute becomes more intense, the efficiency of the algorithms will become as well better and better. And so to some extent, this is being materialized as well in the gross margin, but I will let George further develop.

Yes. We did have a relatively favorable mix in the first quarter. So I do think gross margin did come in on the high side in the first quarter. We said year-over-year, they would be up sequentially, and we still believe that. But I do think the first quarter margin was probably a little bit better than expected. Again, we had a couple of one-time items in there, but I do think ultimately, you will see it still improve on a year-over-year basis, although not quite this high in the out quarters.

Great, thanks, George. And then on the BioPharma side of the business, is there any large contract wins or large contribution considered in your guidance? And where is the biggest medium-term opportunity that you're seeing with biopharma? Is it an early drug discovery and development? Or are you starting to see a lot more interest on the targeted medicine companion diagnostics side from your BioPharma customers?

So yes, thanks for the question, Conor. Ross was just at the AACR conference, which is one of the biggest conferences around cancer research. So he's going to let you know where we stand today.

Thanks, Jurgi. So Conor, as you recall, we did a bit of changes in our BioPharma business last summer. And with that, we've seen a material improvement in the pipeline. And now in this quarter, you're starting to see bookings come through. And so I think in general, we're quite pleased with the progress we've made, particularly in CTAs, CDx, and sponsored testing sort of more on the traditional diagnostic side of things. I think the reality is we have shown good momentum. We are quite pleased with the progress. We are where we expected to be on that side of the business, but I would say, in general, obviously, this is still in its nascent stages as a business. And so from that perspective, we are aggressively pursuing business, but I'll let George maybe comment on how we're reflecting that in the guidance.

Yes. We guided before that we expected pharma to be flat in 2025. So even though we're very excited about some of the opportunities in the pipeline, at least at this point, we are expecting pharma to be flat year-over-year and then ideally a significant benefit in 2026.

Got it, thanks. I appreciate the insights on the tariff impacts and the macro environment. Is there a medium-term opportunity for you, considering you're not selling capital to customers? For instance, could your customers be looking to maximize their capital investments or potentially develop their own software offerings that require larger investments? This might allow you to capture some of that business if they are budget constrained or trying to save on capital expenses.

Yes. Thank you, Conor. So indeed, right, it looks like there is a trend on being somewhat constrained on CapEx investments, obviously, in the world of research activities, but as you know well, we are diagnostics. We are not tools, so we don't sell as a CapEx. We go into the Opex of the hospitals who are being paid on news. So I would say, today, we don't see pressure, and to your point, this might be an opportunity as well, right, because it could be that some hospitals or reference labs, given those new dilemmas, don't want to invest themselves in making their own developments, and they want to use a software like SOPHiA. Ross, we've been interacting with a number of customers around those constraints recently. Maybe you want to highlight where we stand and the little friction we see on our side.

Yes. So, and maybe just to be super clear, we today see very healthy budgets across our customers. So in general, it's quite a solid environment for us, essentially in most geographies around the world. In general, it's quite strong. I would say probably the biggest immediate or near-term impact we are seeing is if you have bought a sequencer and upgraded, you have great desire to fill those flow cells. And so that means more applications, more content, which means players like SOPHiA need to step up and provide you with a menu to be able to make the economics of that purchase viable. And so increasingly, you see those interactions benefiting us. And it's also brought us closer to some of the cap equipment players as I think a number of them see us as a key partner to bring that menu and to bring the validation and to show the ROI so that when you're bringing in-house certain capabilities, you can show that that level of investment was prudent and that you can ultimately not just bring care closer to the patient and improve turnaround times but also drive a financial benefit and an ROI, which is obviously critical for CapEx investment in the current environment. So again, I think it's a net positive for us.

Great. Thanks for all that color.

And your next question comes from the line of Tejas Savant with Morgan Stanley. Please go ahead.

Hi, this is Jason on for Tejas. Thank you for taking our questions. So maybe just to start off, a question on the collaboration with AstraZeneca. So you originally began this collaboration with AstraZeneca in 2023. Could you just talk about the traction you've had from this collaboration in that timeframe? What has it meant for the company's volume and ASP profile? Also, does this new collaboration include MSK-IMPACT? And if not, could including MSK-IMPACT be in the cards? And how are you thinking about other collaboration opportunities in the future, in particular, with large pharma? Thank you.

Yes. Thank you, Jason. I will start and then let Ross take over. So as you may remember, our partnership with AstraZeneca on the diagnostic side started with HRD testing, which was something that the market was missing for the prescription of PARP inhibitors. This was our initial collaboration, where we had worked together on market access needs so that more patients could be properly tested in Europe on HRD. And then this collaboration was expanded to your point, with MSK-ACCESS and MSK-IMPACT. Ross, do you want to give a status on where we stand on ACCESS, IMPACT, and the new collaboration agreement we just signed?

Thanks, Jurgi. And Jason, thanks for the question. So I would say, one, it's great to be aligned with AZ around these efforts, given, obviously, they today have an incredibly robust pipeline and one that matches very well with our offering in menu. So there's a ton of fantastic overlap between the two organizations and our missions, and they obviously have a real desire as well to bring care closer to the patient, improve market access, and we're happy to help them on that journey, so it's a really good partnership up and down in the organization. Now if you look at the success we have had with ACCESS and now IMPACT, obviously, they as well as our own efforts have been really critical to getting that into as many labs as we've penetrated quickly. I would say this is probably for the company one of the fastest and best new product launches in history, and so in that vein, obviously, some of their efforts have helped us there, so we're really appreciative of the partnership. From that standpoint, you can see the recent expansion is kind of evidence of the success, and we expect that to bear very nice fruit not just in the upcoming periods, but over the next several years. This is really a key partnership and product for us. Now I am also pleased to say, as I hinted at before, we've also expanded our outreach with other top pharma and we will have, hopefully, later this year, some further disclosures. But I think you can sort of ascertain that there are others as well that see the world similarly to AZ and see the value that SOPHiA can bring, particularly around CGP testing and liquid biopsy, and so we expect this now to broaden out to others. We publicly talked a bit about J&J as an increasing, I would say, important other partner for us, but I think there will be more. And so again, as Jurgi mentioned, coming off of World CDx and AACR, we really have seen an uptick in interest and now we've got to translate that obviously into bookings and revenue. And so again, we've been conservative, as George stated in our assumptions for this year, but I'm quite confident that the trajectory is pointing in the right direction for us.

Great. That was helpful. Then maybe as a follow-up question, a question on the balance sheet. So, I guess last quarter, SOPHiA reframed your adjusted operating profitability target from year-end 2026 to adjusted EBITDA breakeven in 2027. So, is the current balance sheet sufficient to reach this new target? And how are you thinking about opportunities to strengthen the balance sheet? Thank you.

Yes. George, that's for you.

Yes. No, again, we finished the quarter with $68 million in cash plus another $35 million in undrawn credit line. So, that's a total of over $100 million of available liquidity. Very pleased that we continue to shrink our EBITDA losses, and I think you have seen all the work and the efforts we have done around expense control and improving our gross margins on the COGS side. And again, our loss was less than $10 million this quarter. So certainly, I think that frames us up fairly well. And again, we think our losses will be quite small by the end of 2026, and we will cross over into adjusted EBITDA profitability into 2027.

Great. Congrats on the quarter.

And your next question comes from the line of Daniel Brennan with TD Cowen. Please go ahead.

Good morning, everyone. This is Kyle filling in for Dan. Thank you for taking my questions. I wanted to revisit the guidance and the pace of our implementation. You reaffirmed the guidance for this year, and the implementations were quite strong in the first quarter. Does this affect the expected weighting for the second half? I understand you're still anticipating a second half-heavy year, but does the strong implementation mean some of that weighting might balance out?

Yes, George?

Yes. No, we're still expecting, while we're pleased certainly with first quarter results, we think it is prudent to maintain the guidance at this point and we do still feel, again, given our contracts that we've signed that have not really transferred into routine, that will happen more in the back half of this year. So, we do think we're going to see more growth in Q3 and certainly in Q4. And clearly, in the first quarter, our revenue growth was within the 10% to 17% guidance range that we established, so at this point, we are maintaining our guidance.

Got it. And then is there any detail you're willing to provide on the new customer signings? What percentage of the new signings are U.S. versus OUS? And earlier, you talked about the average size of contracts getting bigger. Can you quantify that at all?

Yes, we can give you some more color on the new logos in terms of the number of logos and where they come from. As you know, we don't disclose dollar values of bookings. Ross, on new logos?

Yes. Thanks, Jurgi. So, in terms of the new customer signings, obviously, we've had, frankly, success around the globe. But I would say there is sort of notable strength coming in North America. And as you think about this year and into next year, I do think relative to our revenue mix, a disproportionate amount will come from the U.S. and those tend to be much larger lands or expands, several times larger than our average. So that is pulling up that ACV number. And I think that number, which again doubled year-on-year, will continue to trend favorably for the remainder of the year. So, I would say, in total, this will obviously show up eventually in our North American revenue growth, which on the clinical side was quite robust in the first quarter, and we expect to be strong throughout the year. But I can tell you the dynamics in general are really strong in terms of the U.S. business, and we're really pleased where that is. And we think, again, this will be one of the key growth drivers for us in the back half of the year and into 2026.

Got it. Thanks, guys.

Your next question comes from the line of Subbu Nambi with Guggenheim. Please go ahead.

Hey guys, good morning. Thank you for taking the questions. You churned out a few smaller customers who weren't contributing revenue. So, we were wondering what is the split on customer number who aren't material contributors versus those who are?

Ross?

Yes. So Subu, so obviously, as you think about different regions, right, obviously, an IDN or an AMC in the U.S. or U.K. or even France is going to be quite different than someone in Costa Rica or in Thailand or Malaysia, etcetera. So I would say, in total, it's sometimes challenging, particularly in more of the emerging markets to know when we sign a customer what the full potential is but I would say, increasingly, again, and this is around this ACV comment, we've been more focused on, let's say, the top 500 cancer centers in the world. And there, obviously, we know the size and we know the patient sort of levels. And so I think, again, you'll probably see some dynamic change in that mix, but again, when you're running a network model and the diversity of what we have, you're trying to play for the broadest network. And so we'll continue to obviously entertain customers in all of these emerging markets for oncology. But obviously, it will at times lead to at least the churn customer number being elevated, but not the churn percentage. We're still very pleased with where that remains in the low single digits, which is a world-class number for software.

That's awesome. Can you provide some color on cross-selling the MSK-ACCESS and MSK-IMPACT offerings? I know MSK-ACCESS had 34 adopters as of February 2025. I'm just wondering how many adopters of both assays do you have today?

Yes. Thank you, Subbu. So indeed, MSK-ACCESS and MSK-IMPACT are, we believe, applications which have a bright future, but it's still pretty early, yes. So on MSK-ACCESS, the launch has been successful. We have had adoption of MSK-ACCESS in all continents, as you said, for about 30 customers already and we expect basically the numbers to really play out as we progress and we get more and more utilization. But I would say we're still very much at the beginning and with a decentralized solution that everyone can adopt, probably MSK-ACCESS is pretty unique in its category. So we have high expectations, but still work to do so that on the market access side, we see more and more volume adoption. When it comes to MSK Impact, say the competitive landscape is different. You already had some people that adopted comprehensive genomic profiling solutions in the market. So the market already exists, more competitive, but the capabilities of MSK-IMPACT because of its nature with tumor normal are pretty unique. And so there, we are as well very confident that in conjunction with MSK-ACCESS, we will have a number of customers that is going to grow in the adoption of MSK-IMPACT. The two tends to go very well together, MSK-IMPACT for the first diagnosis and after MSK-ACCESS for the longitudinal follow-up of the patient as the patient is being treated.

Helpful, Jurgi. And one last one. You guys announced the expanded agreement with AstraZeneca to increase the number of MSK-ACCESS adopters from 20 to 30 this year. Was this already contemplated in your guidance given you didn't raise your guidance today? Or if not, would completing this just present an upside to the guide? Or is the time frame about committing to adopt the solution and not necessarily ramping up and generating revenue?

George?

Yes. Again, when we sign somebody for MSK Access, I mean, it is a rather detailed application, and a lot goes into the validation and bringing it live. So it does have probably a little bit longer of a runway in terms of somebody signing a contract to actually going live, but we're still quite bullish about the opportunities here going forward.

No further questions at this time. I would like to turn it back to Jurgi Camblong for closing remarks.

Thank you all for the questions and looking forward to updating you in the next event or soon in an event in New York, ready to meet investors. Have a good day.

This concludes today's conference call. Thank you all for joining. You may now disconnect.